AU2013282286A1 - Compositions and methods for treating or preventing pneumovirus infection and associated diseases - Google Patents

Compositions and methods for treating or preventing pneumovirus infection and associated diseases Download PDF

Info

Publication number
AU2013282286A1
AU2013282286A1 AU2013282286A AU2013282286A AU2013282286A1 AU 2013282286 A1 AU2013282286 A1 AU 2013282286A1 AU 2013282286 A AU2013282286 A AU 2013282286A AU 2013282286 A AU2013282286 A AU 2013282286A AU 2013282286 A1 AU2013282286 A1 AU 2013282286A1
Authority
AU
Australia
Prior art keywords
mdt
crystal form
pattern
diffraction peaks
dihydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2013282286A
Other languages
English (en)
Inventor
Robert O. Cook
Eugene R. Reynolds
Boris Shekunov
Siead I. Zegar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Microdose Therapeutx Inc
Original Assignee
Microdose Therapeutx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Microdose Therapeutx Inc filed Critical Microdose Therapeutx Inc
Publication of AU2013282286A1 publication Critical patent/AU2013282286A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2013282286A 2012-06-29 2013-06-28 Compositions and methods for treating or preventing pneumovirus infection and associated diseases Abandoned AU2013282286A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261666258P 2012-06-29 2012-06-29
US61/666,258 2012-06-29
PCT/US2013/048723 WO2014005098A2 (en) 2012-06-29 2013-06-28 Compositions and methods for treating or preventing pneumovirus infection and associated diseases

Publications (1)

Publication Number Publication Date
AU2013282286A1 true AU2013282286A1 (en) 2015-01-22

Family

ID=49778754

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013282286A Abandoned AU2013282286A1 (en) 2012-06-29 2013-06-28 Compositions and methods for treating or preventing pneumovirus infection and associated diseases

Country Status (17)

Country Link
US (2) US9040569B2 (enExample)
EP (1) EP2867216A4 (enExample)
JP (1) JP2015524391A (enExample)
KR (1) KR20150037946A (enExample)
CN (1) CN104507918A (enExample)
AU (1) AU2013282286A1 (enExample)
BR (1) BR112014032290A2 (enExample)
CA (1) CA2877941A1 (enExample)
EA (1) EA201590124A1 (enExample)
HK (2) HK1203956A1 (enExample)
IL (1) IL236476A0 (enExample)
IN (1) IN2014DN10680A (enExample)
MX (1) MX2014015340A (enExample)
NZ (1) NZ628880A (enExample)
TW (1) TWI516283B (enExample)
WO (1) WO2014005098A2 (enExample)
ZA (1) ZA201409073B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2867216A4 (en) 2012-06-29 2015-12-09 Microdose Therapeutx Inc COMPOSITIONS AND METHODS OF TREATING PNEUMOVIRAL INFECTIONS AND ASSOCIATED DISEASES
EP3233807B1 (de) * 2014-12-18 2019-09-04 MetrioPharm AG Kristalline form von 5-amino-2,3-dihydrophthalazin-1,4-dion natriumsalz, diese enthaltende pharmazeutische zubereitungen und verfahren zu ihrer herstellung
JP2018535277A (ja) * 2015-11-30 2018-11-29 ノヴァス・セラピューティクス・インコーポレーテッド 耳科学的予防および処置のための組成物および方法
WO2018071445A1 (en) 2016-10-11 2018-04-19 Microdose Therapeutx, Inc. Inhaler and methods of use thereof
MX2021001820A (es) * 2018-09-14 2021-04-28 Pharmosa Biopharm Inc Composicion farmaceutica para la liberacion controlada de farmacos acidos debiles y usos de los mismos.
CN109827875A (zh) * 2019-04-10 2019-05-31 上海市食品药品检验所 一种用于测定吸入制剂溶出度的装置和方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495580B1 (en) * 1998-01-29 2002-12-17 Viropharma Incorporated Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases
WO1999038508A1 (en) 1998-01-29 1999-08-05 Viropharma Incorporated Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases
WO2002059132A1 (en) 2001-01-26 2002-08-01 Viropharma Incorporated Intermediate compounds useful for making antiviral compounds
EP1545513A2 (en) 2002-08-09 2005-06-29 Viropharma Incorporated Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases
EP1539691A2 (en) 2002-08-09 2005-06-15 Viropharma Incorporated Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases
EP2867216A4 (en) 2012-06-29 2015-12-09 Microdose Therapeutx Inc COMPOSITIONS AND METHODS OF TREATING PNEUMOVIRAL INFECTIONS AND ASSOCIATED DISEASES

Also Published As

Publication number Publication date
TWI516283B (zh) 2016-01-11
TW201416093A (zh) 2014-05-01
KR20150037946A (ko) 2015-04-08
WO2014005098A2 (en) 2014-01-03
WO2014005098A3 (en) 2014-02-27
MX2014015340A (es) 2015-03-05
ZA201409073B (en) 2016-08-31
EP2867216A4 (en) 2015-12-09
US9040569B2 (en) 2015-05-26
IL236476A0 (en) 2015-02-26
IN2014DN10680A (enExample) 2015-08-28
NZ628880A (en) 2016-08-26
US20140005239A1 (en) 2014-01-02
JP2015524391A (ja) 2015-08-24
US9504672B2 (en) 2016-11-29
HK1210163A1 (en) 2016-04-15
CN104507918A (zh) 2015-04-08
CA2877941A1 (en) 2014-01-03
HK1203956A1 (en) 2015-11-06
US20150209328A1 (en) 2015-07-30
EP2867216A2 (en) 2015-05-06
BR112014032290A2 (pt) 2017-06-27
EA201590124A1 (ru) 2015-06-30

Similar Documents

Publication Publication Date Title
US9504672B2 (en) Compositions and methods for treating or preventing pneumovirus infection and associated diseases
KR101473028B1 (ko) 인플루엔자 치료제
JP5665538B2 (ja) （１ｓ，２ｓ，３ｓ，４ｒ）−３−［（１ｓ）−１−アセチルアミノ−２−エチル−ブチル］−４−グアニジノ−２−ヒドロキシ−シクロペンチル−１−カルボン酸水和物及びその使用
TW202333743A (zh) (s)-2-乙基丁基2-(((s)-(((2r,3s,4r,5r)-5-(4-胺基吡咯并[2,1-f] [1,2,4]三嗪-7-基)-5-氰基-3,4-二羥基四氫呋喃-2-基)甲氧基)(苯氧基)磷醯基)胺基)丙酸酯之結晶形式
BR112017005104B1 (pt) Derivados de 5,6-di-hidro-4h-benzotieno-[2,3-d]azepina, seus usos, composição farmacêutica e processo para a preparação dos mesmos
US20070225326A1 (en) Montelukast amantadine salt
JP7772899B2 (ja) ニコチニルアルコールエーテル誘導体のマレイン酸塩、その結晶形、及びその使用
ES2899367T3 (es) Forma amorfa de trifenatato de vilanterol y procedimientos para su preparación
US9339487B2 (en) Dry powder pharmaceutical composition for inhalation
WO2020183227A1 (en) Treating influenza using substituted polycyclic pyridone derivatives and prodrugs thereof in a subject having influenza and a complication risk factor
CN115666510A (zh) 用于治疗或预防病毒感染的氯法齐明组合物和方法
RU2842252C1 (ru) Твердые формы 2-(имидазол-4-ил)этанамида пентандиовой-1,5 кислоты
RU2821102C2 (ru) Твердые формы 2-(имидазол-4-ил)этанамида пентандиовой-1,5 кислоты
JP2007277228A (ja) アンドラストの新規で安定な結晶構造体
HK40083799A (en) Clofazimine composition and method for the treatment or prophylaxis of viral infections
EA050044B1 (ru) Твердые формы 2-(имидазол-4-ил)этанамида пентандиовой-1,5 кислоты
EA047921B1 (ru) Твердые формы 2-(имидазол-4-ил)этанамида пентандиовой-1,5 кислоты
CN118290383A (zh) 二氢杨梅素与吡啶甲酸共晶及制备方法和其药物组合物与用途
HK1160004A (en) Dry powder pharmaceutical composition for inhalation

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application